Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s42003-021-02220-z http://scihub22266oqcxt.onion/10.1038/s42003-021-02220-z 34083759!8175744!34083759     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Commun+Biol 2021 ; 4 (1): 682 Nephropedia Template TP {{tp|p=34083759|t=2021. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus |pdf=|usr=}}{{34083759}} gab.com Text SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus JO: Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=34083759 #FOAvip An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19. Twit Text FOAVip SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus ????Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=34083759 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34083759 #FOAvip English Wikipedia <ref>{{Cite pmid|34083759}}</ref> SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus #MMPMID34083759 Chen J; Dai L; Barrett L; James J; Plaisance-Bonstaff K; Post SR; Qin Z Commun Biol 2021[Jun]; 4 (1): 682 PMID34083759show ga An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19. |*Virus Activation/drug effects[MESH] |Antiviral Agents/*pharmacology[MESH] |Azithromycin/pharmacology[MESH] |Benzamidines/pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*complications[MESH] |Cell Line[MESH] |Guanidines/pharmacology[MESH] |Herpesviridae Infections/chemically induced/etiology[MESH] |Herpesvirus 8, Human/drug effects/*physiology[MESH] |Humans[MESH] |Oncogenic Viruses/drug effects/physiology[MESH] |SARS-CoV-2/drug effects/*physiology[MESH] |Sarcoma, Kaposi/chemically induced/*etiology[MESH]SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation (epmc).pdf DeepDyve Pubget Overpricing